Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2780301 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2780301 | EXPERIMENTAL | Part A: daily dosing Part B (if determined as needed by pharmacokinetic, pharmacodynamic, and safety data): twice daily dosing Part C: Dose and frequency as determined by Parts A and B of the study. |
| Name | Type | Description |
|---|---|---|
| LY2780301 | DRUG | Administered orally, daily for two 28-day cycles. Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression. |
Inclusion Criteria: * Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic (including Non-Hodgkin's Lymphoma). The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therap...
LY2780301 is an investigational small molecule being studied for the treatment of advanced or metastatic cancer, including metastases and neoplasms. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
LY2780301 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY.
LY2780301 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
LY2780301 has one completed clinical trial, NCT01115751, titled "A Study in Patients With Advanced or Metastatic Cancer." This Phase 1 study enrolled 80 participants in Spain and was not randomized or blinded.
LY2780301 is a small molecule therapeutic being investigated for its anti-cancer activity in patients with advanced or metastatic cancer. Its specific molecular target has not been disclosed in available information.